Evidence map›Paper›PMID 40089870›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Integration of Circulating Tumor DNA and Metabolic Parameters on

Leilei Wu, Zhenshan Zhang, Chenxue Jiang, Li Li, Xiaojiang Sun, Menglin Bai, Ming Liu, Kangli Xiong, Jinbiao Shang, Jinming Yu and 3 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. [European journal of nuclear medicine and molecular imaging · 2026
    Article
  3. Review
  4. Review
  5. Integrin αvβ6-Targeted PET/CT Imaging of Non-Small Cell Lung Cancer with [Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Observational
  6. Article
  7. Review
  8. Integration of Circulating Tumor DNA and Metabolic Parameters onAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  9. Article
  10. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Leilei WuDepartment of Radiation Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.ORCID https://orcid.org/0000-0003-0060-2012
Zhenshan ZhangDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.ORCID https://orcid.org/0000-0002-6846-4464
Chenxue JiangDepartment of Radiation Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
Li LiDepartment of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China.
Xiaojiang SunDepartment of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, 310022, China.
Menglin BaiDepartment of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China.
Ming LiuDepartment of Radiation Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
Kangli XiongGeneseeq Research Institute, Nanjing Geneseeq Technology Inc, Nanjing, 210008, China.
Jinbiao ShangDepartment of Thyroid Surgery, Zhejiang Cancer Hospital, Hangzhou, 310022, China.
Jinming YuDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, 250117, China.
Shuanghu YuanDepartment of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China.
Yang YangDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
Yaping XuDepartment of Radiation Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.ORCID https://orcid.org/0009-0002-9109-1958

Funding

Beijing Bethune Charitable Foundation flzh202112Development Funds of the Department of RadiotherapyHospital-level Key Project of Shanghai Pulmonary Hospital FKLY20006National Natural Science Foundation of China 82473560National Science Foundation for Distinguished Young Scholars of China 52325106Natural Science Foundation of Zhejiang Province LTGY24H010003Science and Technology Innovation Action Plan of the Science and Technology Commission of Shanghai Municipality 19411950300Science and Technology Innovation Action Plan of the Science and Technology Commission of Shanghai Municipality 23Y11908700Talent Introduction Program of Shanghai Pulmonary Hospital 20180101Technical Standards Project of the Science and Technology Commission of Shanghai Municipality 21DZ2201900Zhejiang Provincial Traditional Chinese Medicine Science and Technology Program 2024ZL306
6 · The paper itself

Abstract

This prospective study explores the prognostic value of circulating tumor DNA (ctDNA) and positron emission tomography/computed tomograpy (PET/CT) in unresectable locally advanced non-small cell lung cancer (LA-NSCLC) treated with definitive chemoradiotherapy (CRT). The discovery set includes 62 patients, with 62 baseline and 53 post-CRT plasma samples. PET/CT is performed at baseline, and 33 patients undergo mid-treatment scans after 40 Gy. Baseline ctDNA is detected in 71.0% of patients. Pre-treatment ctDNA concentration correlates with total metabolic tumor volume (TMTV) (p < 0.001) and total lesion glycolysis (TLG) (p = 0.001) but not treatment response or survival. However, patients with undetectable ctDNA and low TMTV show significantly longer progression-free survival (PFS) (34.2 vs 10.1 months, p = 0.027). Post-CRT, ctDNA is detected in 47.2% of patients, while ctDNA concentration (p = 0.005) and variant allele frequency (VAF) (p = 0.005) significantly decline. Undetectable post-CRT ctDNA associates with longer PFS (p < 0.001) and overall survival (OS) (p = 0.001). Higher ∆TMTV correlates with improved PFS and OS. Similar findings were obtained in a test of 19 patients. These results highlight post-CRT ctDNA and ∆TMTV as robust prognostic markers, potentially identifying patients who may forgo ICI consolidation.

Indexed as

Carcinoma, Non-Small-Cell LungCirculating Tumor DNAFluorodeoxyglucose F18Lung NeoplasmsPositron Emission Tomography Computed TomographyAdultAgedAged, 80 and overChemoradiotherapyFemaleHumansMaleMiddle AgedPrognosisProspective StudiesTreatment OutcomeCirculating Tumor DNAFluorodeoxyglucose F18ctDNAdefinitive chemoradiotherapyimmune checkpoint inhibitorsLA‐NSCLCPET metabolic parameters

Identifiers

PMID40089870
PMCPMC11967874

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.